Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $15.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 119.62% from the company’s current price.

COYA has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, November 11th.

Coya Therapeutics Trading Down 2.4 %

Shares of NASDAQ COYA opened at $6.83 on Thursday. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The company has a 50-day moving average of $5.87 and a two-hundred day moving average of $6.40. The company has a market cap of $114.13 million, a PE ratio of -10.51 and a beta of 0.47.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, equities research analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Insider Transactions at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of Coya Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $7.34 per share, with a total value of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased 9,510 shares of company stock worth $69,615 in the last three months. Insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

Several hedge funds have recently bought and sold shares of COYA. Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at $401,000. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics in the third quarter valued at about $169,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics in the second quarter valued at about $101,000. CM Management LLC raised its position in shares of Coya Therapeutics by 11.1% during the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after purchasing an additional 15,941 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after purchasing an additional 4,485 shares during the period. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.